IGF-1R inhibitor

DRUG CLASS:

IGF-1R inhibitor

News alerts, weekly reports and conference planners

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2	SY-707 Sensitive: C2 – Inclusion Criteria SY-707 Sensitive : C2
IGF1R underexpression	Ewing Sarcoma	IGF1R underexpression	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
IGF1 elevation	Ewing Sarcoma	IGF1 elevation	Ewing Sarcoma	CP-751,871 Sensitive: C3 – Early Trials CP-751,871 Sensitive : C3	CP-751,871 Sensitive: C3 – Early Trials CP-751,871 Sensitive : C3
PTPRD R995C	Ewing Sarcoma	PTPRD R995C	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3	mTOR inhibitor + IGF-1R inhibitor Sensitive: C3 – Early Trials mTOR inhibitor + IGF-1R inhibitor Sensitive : C3
PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	PTPRD V253I + PTPRD W775stop	Ewing Sarcoma	IGF-1R inhibitor Sensitive: C3 – Early Trials IGF-1R inhibitor Sensitive : C3	IGF-1R inhibitor Sensitive: C3 – Early Trials IGF-1R inhibitor Sensitive : C3
IGF1 elevation	Pancreatic Cancer	IGF1 elevation	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGF2 elevation	Pancreatic Cancer	IGF2 elevation	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGFBP2-L	Pancreatic Cancer	IGFBP2-L	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGFBP3 elevation	Pancreatic Cancer	IGFBP3 elevation	Pancreatic Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
HR negative	HER2 Negative Breast Cancer	HR negative	HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IGFBP5-L	HER2 Negative Breast Cancer	IGFBP5-L	HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
IRS1-L	HER2 Negative Breast Cancer	IRS1-L	HER2 Negative Breast Cancer	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3	AMG 479 Sensitive: C3 – Early Trials AMG 479 Sensitive : C3
PRDX1 overexpression	Hepatocellular Cancer	PRDX1 overexpression	Hepatocellular Cancer	ASP7487 Sensitive: C3 – Early Trials ASP7487 Sensitive : C3	ASP7487 Sensitive: C3 – Early Trials ASP7487 Sensitive : C3
REST signature	Glioblastoma	REST signature	Glioblastoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
ALK F1174L	Neuroblastoma	ALK F1174L	Neuroblastoma	AZD3463 Sensitive: D – Preclinical AZD3463 Sensitive : D	AZD3463 Sensitive: D – Preclinical AZD3463 Sensitive : D
ALK D1091N	Neuroblastoma	ALK D1091N	Neuroblastoma	AZD3463 Sensitive: D – Preclinical AZD3463 Sensitive : D	AZD3463 Sensitive: D – Preclinical AZD3463 Sensitive : D
IGF1R expression	Ewing Sarcoma	IGF1R expression	Ewing Sarcoma	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D
IGF1R expression	Osteosarcoma	IGF1R expression	Osteosarcoma	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D
IGF1R expression	Soft Tissue Sarcoma	IGF1R expression	Soft Tissue Sarcoma	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D	IGF-1R inhibitor Sensitive: D – Preclinical IGF-1R inhibitor Sensitive : D
FUS-ERG fusion	Ewing Sarcoma	FUS-ERG fusion	Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
CDKN2A deletion	Ewing Sarcoma	CDKN2A deletion	Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
PAK4 deletion	Ewing Sarcoma	PAK4 deletion	Ewing Sarcoma	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D	ASP7487 Sensitive: D – Preclinical ASP7487 Sensitive : D
IGF1R overexpression	Colorectal Cancer	IGF1R overexpression	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D
IGFBP6 underexpression	Colorectal Cancer	IGFBP6 underexpression	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D
IR overexpression	Colorectal Cancer	IR overexpression	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D
IRS2 amplification	Colorectal Cancer	IRS2 amplification	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	BMS-754807 Resistant: D – Preclinical BMS-754807 Resistant : D	BMS-754807 Resistant: D – Preclinical BMS-754807 Resistant : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D
IGF2 elevation	Ovarian Cancer	IGF2 elevation	Ovarian Cancer	AMG 479 Sensitive: D – Preclinical AMG 479 Sensitive : D	AMG 479 Sensitive: D – Preclinical AMG 479 Sensitive : D
PTEN mutation	Ovarian Cancer	PTEN mutation	Ovarian Cancer	AMG 479 Resistant: D – Preclinical AMG 479 Resistant : D	AMG 479 Resistant: D – Preclinical AMG 479 Resistant : D
ALK A348D	Leukemia	ALK A348D	Leukemia	GSK 1838705A Sensitive: D – Preclinical GSK 1838705A Sensitive : D	GSK 1838705A Sensitive: D – Preclinical GSK 1838705A Sensitive : D

IGF-1R inhibitor

IGF-1R inhibitor

Associations(40)

Associations
(40)